Vildoff-M 50/500 mg Tablet

Vildoff-M 50/500 mg Tablet contains Vildagliptin 50 mg + Metformin 500 mg (tablet). Prescription required.

Type 2 diabetes mellitus (to improve blood glucose control along with diet and exercise), especially when blood sugar is not adequately controlled with metformin or other oral antidiabetic medicines

Vildagliptin is a DPP-4 inhibitor that increases incretin hormones (GLP-1, GIP), leading to increased insulin release and reduced glucagon secretion in a glucose-dependent manner. Metformin decreases hepatic glucose production and improves insulin sensitivity, lowering blood glucose levels.

Oral tablet. Take as prescribed by a doctor, usually with meals to reduce stomach upset. Swallow whole with water; do not crush/chew. Regularly monitor blood glucose and follow diet/exercise advice.

Nausea, vomiting, diarrhea, abdominal pain, loss of appetite, metallic taste, headache, dizziness, upper respiratory tract infection, hypoglycaemia (more likely with other antidiabetics), increased liver enzymes

Prescription-only antidiabetic. Metformin may rarely cause lactic acidosis—risk increases with kidney impairment, dehydration, heavy alcohol use, severe infection, heart/respiratory failure; stop and seek care if rapid breathing, severe weakness, abdominal pain occur. Use caution in renal impairment; dose adjustment/avoid based on eGFR. Vildagliptin may affect liver—check LFTs periodically and stop if persistent elevation or jaundice. Risk of pancreatitis—seek care for severe persistent abdominal pain. Temporarily withhold metformin before/after iodinated contrast or major surgery as advised. Not for type 1 diabetes or diabetic ketoacidosis.

Alcohol (increases lactic acidosis risk), iodinated contrast media (temporary stoppage needed), carbonic anhydrase inhibitors (e.g., topiramate, acetazolamide) may increase metabolic acidosis risk, cationic drugs affecting renal tubular secretion (e.g., cimetidine) may increase metformin levels, diuretics/ACE inhibitors/NSAIDs (may affect kidney function), corticosteroids and sympathomimetics (may raise glucose), insulin or sulfonylureas (increased hypoglycaemia risk)

Store below 25°C in a cool, dry place. Protect from moisture and direct light. Keep out of reach of children.

Galvus Met 50/500 Tablet, Jalra-M 50/500 Tablet, Zomelis Met 50/500 Tablet, Vildamet 50/500 Tablet, Vildagliptin+Metformin 50/500 tablets (generic equivalents)